CDK4-IN-1
CAS No. 1256963-02-6
CDK4-IN-1 ( LEE011 analog; CDK4-IN-1; CDK4IN-1; CDK4-IN1 )
Catalog No. M11055 CAS No. 1256963-02-6
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 873 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK4-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
-
DescriptionCDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
-
SynonymsLEE011 analog; CDK4-IN-1; CDK4IN-1; CDK4-IN1
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK4; Cyclin D1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1256963-02-6
-
Formula Weight440.97
-
Molecular FormulaC22H29ClN8
-
Purity>98%(HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESCN(C1CCN(C2=CN=C(NC3=NC=CC(C4=C(C(C)C)NN=C4Cl)=N3)C=C2)CC1)C
-
Chemical Name4-(3-Chloro-5-propan-2-yl-1H-pyrazol-4-yl)-N-[5-[4-(dimethylamino)piperidin-1-yl]pyridin-2-yl]pyrimidin-2-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Cho YS, et al. J Med Chem. 2010 Nov 25;53(22):7938-57.
molnova catalog
related products
-
Ro-3306
Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
-
Indirubin-3-monoxime
Indirubin-3-monoxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
-
Dalpiciclib
Dalpiciclib is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4?nM and 9.9?nM, respectively.